Sunshine Biopharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Sunshine Biopharma Inc. on December 9, 2022, reporting an event that occurred on December 6, 2022. The Company is incorporated in Colorado and maintains its principal executive offices in Pointe-Claire, Quebec, Canada. Its common stock (SBFM) and warrants (SBFMW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the trading price of the common stock, which closed below $1.00 for 30 consecutive trading days leading up to the report date.
Material Changes
On December 6, 2022, the Company received a notification from Nasdaq stating it no longer meets the Minimum Bid Price Requirement under Marketplace Rule 5550(a)(2). This deficiency is due to the closing bid price of the common stock remaining below $1.00 for 30 consecutive trading days. The notification has no immediate effect on the listing status.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days from December 6, 2022, until June 5, 2023, to regain compliance.
- Compliance Criteria: To cure the deficiency, the bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days before June 5, 2023.
- Extension Options: If compliance is not achieved by the initial deadline, the Company may be eligible for an additional 180-day period. This requires meeting all other initial listing standards (except bid price) and potentially effecting a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance or is deemed ineligible for an extension, Nasdaq may delist the securities.
- Management Action: Management intends to actively monitor the bid price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of SBFM to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if the initial compliance window is met.
- Review future filings for announcements regarding a potential reverse stock split if the initial compliance period expires without resolution.
- Check for any subsequent Nasdaq notifications regarding the extension of the compliance period or potential delisting.